ARENA, FLAVIA
 Distribuzione geografica
Continente #
NA - Nord America 134
EU - Europa 116
AS - Asia 104
SA - Sud America 17
AF - Africa 3
Totale 374
Nazione #
US - Stati Uniti d'America 125
IT - Italia 37
CN - Cina 35
SG - Singapore 32
RU - Federazione Russa 20
HK - Hong Kong 19
DE - Germania 18
FI - Finlandia 18
BR - Brasile 12
VN - Vietnam 8
CA - Canada 5
PL - Polonia 5
ES - Italia 4
GB - Regno Unito 4
IN - India 4
VE - Venezuela 3
ZA - Sudafrica 3
AT - Austria 2
JM - Giamaica 2
LT - Lituania 2
MX - Messico 2
SA - Arabia Saudita 2
AL - Albania 1
BD - Bangladesh 1
CO - Colombia 1
FR - Francia 1
IE - Irlanda 1
JP - Giappone 1
KG - Kirghizistan 1
LV - Lettonia 1
NL - Olanda 1
SE - Svezia 1
TR - Turchia 1
UY - Uruguay 1
Totale 374
Città #
Dallas 32
Singapore 21
Hong Kong 19
Ashburn 15
Beijing 13
Munich 12
New York 12
Helsinki 10
Rome 9
Shanghai 9
Boardman 8
Turku 8
Los Angeles 7
Milan 7
Moscow 6
Düsseldorf 4
Warsaw 4
Brooklyn 3
Buffalo 3
Chennai 3
Seattle 3
Toronto 3
Charlotte 2
Hanoi 2
Johannesburg 2
Montreal 2
Redondo Beach 2
Serrone 2
The Dalles 2
Vilnius 2
Washington 2
Amsterdam 1
Ankara 1
Araçoiaba da Serra 1
Betim 1
Bishkek 1
Boves 1
Bắc Giang 1
Can Tho 1
Catanduva 1
Changsha 1
Chicago 1
Chongqing 1
Columbus 1
Delhi 1
Dublin 1
El Dorado 1
Extrema 1
Haiphong 1
Ho Chi Minh City 1
Houston 1
Itajaí 1
Jacksonville 1
Jequié 1
Jinan 1
Lauterbourg 1
London 1
Magé 1
Maracaibo 1
Maracay 1
Marshfield 1
Medellín 1
Medina 1
Mexico City 1
Montevideo 1
Orem 1
Pavia 1
Phoenix 1
Poplar 1
Querétaro 1
Ribeirão Preto 1
Riga 1
Riyadh 1
Santa Clara 1
Shenyang 1
Stockholm 1
Tapejara 1
Teresina 1
Tokyo 1
Uberlândia 1
Wroclaw 1
Totale 279
Nome #
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 92
Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers 71
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 60
Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients 58
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment 56
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern 43
Totale 380
Categoria #
all - tutte 2.061
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.061


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202320 0 0 0 0 0 0 0 0 8 1 11 0
2023/202479 6 15 6 1 5 28 8 3 0 3 0 4
2024/2025123 5 7 1 2 2 11 8 3 27 12 17 28
2025/2026158 25 16 38 41 32 6 0 0 0 0 0 0
Totale 380